ReviewCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2013
Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.
Review in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Exploring the Ethics of Implementation of Epigenomics Technologies in Cancer Screening: A Focus Group Study.Epigenetics insights · 2021Article
- Prevention in the age of personal responsibility: epigenetic risk-predictive screening for female cancers as a case study.Journal of medical ethics · 2020Article
- Identification of aberrantly methylated‑differentially expressed genes and gene ontology in prostate cancer.Molecular medicine reports · 2020Article
- Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?Journal of personalized medicine · 2019Review
- Review
- Epigenetic Biomarkers in Colorectal Cancer.Molecular diagnosis & therapy · 2017Review
- Core Canonical Pathways Involved in Developing Human Glioblastoma Multiforme (GBM).International journal of scientific research in science, engineering and technology · 2017Article
- DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Disease markers · 2017Review
- Role of microRNA-4458 in patients with non-small-cell lung cancer.Oncology letters · 2016Article
- Genome-wide copy number variation (CNV) detection in Nelore cattle reveals highly frequent variants in genome regions harboring QTLs affecting production traits.BMC genomics · 2016Article
- Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges.Personalized medicine · 2016Article
- Peripheral blood mitochondrial DNA copy number, length heteroplasmy and breast cancer risk: a replication study.Carcinogenesis · 2015Article
- Personalized medicine in hematology - A landmark from bench to bed.Computational and structural biotechnology journal · 2014Review
- Collaborative cancer epidemiology in the 21st century: the model of cancer consortia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013Review
- Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma.World journal of gastroenterology · 2013Article
- Transforming epidemiology for 21st century medicine and public health.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Remarkable progress has been made in the last decade in new methods for biologic measurements using sophisticated technologies that go beyond the established genome, proteome, and gene expression platforms. These methods and technologies create opportunities to enhance cancer epidemiologic studies. In this article, we describe several emerging technologies and evaluate their potential in epidemiologic studies. We review the background, assays, methods, and challenges and offer examples of the use of mitochondrial DNA and copy number assessments, epigenomic profiling (including methylation, histone modification, miRNAs, and chromatin condensation), metabolite profiling (metabolomics), and telomere measurements. We map the volume of literature referring to each one of these measurement tools and the extent to which efforts have been made at knowledge integration (e.g., systematic reviews and meta-analyses). We also clarify strengths and weaknesses of the existing platforms and the range of type of samples that can be tested with each of them. These measurement tools can be used in identifying at-risk populations and providing novel markers of survival and treatment response. Rigorous analytic and validation standards, transparent availability of massive data, and integration in large-scale evidence are essential in fulfilling the potential of these technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.